Stop 1,2, and 3. PROBLEM-SOLVING APPLICATION CASE (PSAC) Group Forms to Amp Up R
ID: 368471 • Letter: S
Question
Stop 1,2, and 3.
PROBLEM-SOLVING APPLICATION CASE (PSAC) Group Forms to Amp Up Research Major drug companies and nonprofit research groups Three Projects would never put aside flerce competition and conflicting Scientists from the NIH and its industry partners selected agendas just to crack some of the world's most challenging three focal diseases: diseases, would they? Except they did Alzheimer's disease. · early 2014, the National Institutes of Health (NIH) an Type 2 diabetes. In nounced th nership (AMP) to target some of the most challenging diseases. And to accelerate potential cures, they all agreed to share "scientists, tissue and blood samples, and data. in a five-year collaborative effort.-9 e creation of the Accelerating Medicines Part- The auto-immune diseases of rheumatoid arthritis and lupus Egos at the D The project is unique. "We are getting together in a way that has not happened before, Dr. Francis S. Collins, direc- tor of the National Institutes of Health, told The New York Competition through Cooperation This deal, put together by the NIH, all par- ticipants. "By pooling their brightes discoveries," The Woll Street Journal reports, "they hope to put together a research system that can decipher the diseases in ways each hasn't been able to on its own."9 The Journal notes that the costs to the participants are much lower than they would be when working on their creates wins for all par- s. We are bringing scientists from di tives into the same room. They will leave their egos at the door, leave their affiliations at the door The Times reports that such a coliaboration would have been impossible five years ago, quoting Dr. Mikael Dolsten, president of worldwide research and develop- ment at Pfizer. "It was a different time, Dr. Dolsten said t minds and best lab own. In fact, the total budget for the partnership is $1 Cmpanies had the view that going alone would million, split roughly between the NIH at $118.9 million and industry at $110.6 million. These amounts are dramatically lower than the $350 million average cost for the discovery and development of a single drug. Beyond reducing the financial costs, this collaboration also spreads the risk, as 95% of experimental medicines to Who's Who Industry participants include household names. The ten commercial partners are AbbVie, Biogen Idec, Bristol- fail to be both effective Myers Squibb, GlaxoSmithkline, Johnson & Johnson, Lilly, Merck, Pfizer, Sanofi, and Takeda. Nonprofit partners are the Alzheimer's Association, the American Diabetes Asso- ciation, the Arthritis Foundation, the Lupus Foundation of America, the Lupus Research Institute/Alliance for Lupus Not Just Cost Savings The NIH identifies benefits beyond cutting research Research, the Foundation for costs: shorter development time, improved prospects for Foundation, PhRMA, t success, and increased range of theraples. "Under tion, and standing the biological pathways underlying disease and the NIH, the Geoffrey Beene the Rheumatology Research Founda- lead to more rational drug desin an betdes taiteeApply the 3-Stop Problem-Solving lead to more rational drug design and better tailored therapies."94 the NIH says. The agency predicts that the projects will enable more robust clinical trials and re- duce the number of failures in Phase II and Phase IIl clin- edge of OB presented in this chapter to the above case ical trials. Approach to OB Referring to Figure 8.4 and your notes, apply the knowi Applying this knowledge should enable you to recommend realistic and effective solutions Stop 1: What is the problem? Early Stage and Open Source One reason why the coalition works is because the com- petitors are collaborating on the earliest stage of the re- search. The NIH says that the project shouldn't face antitrust concerns because it consists of early research andBased on considering the above two questions, what will make all results freely available to the public dentify the outcomes that are important in this case. Which of these outcomes are not being achieved in is the most important problem in this case? Groups and Teams CHAPTER 8 287Explanation / Answer
Stop 1:
1.
The collaboration should produce the following important outcomes in this case:
A. A formation of team that works closely as a team and share the knowledge with each other
B. Getting breakthrough solutions of the diseases mentioned in the case so that NIH achieves the objective
C. Make an efficient framework of the research that is solution oriented
D. Building of cooperation and companies working on the project should also expand the area of research and include other new diseases
E. Sharing of the past data so that research process is fast processed
2.
As per the give details of the case, it is about the formation of the team and working on common goals and objective. Though, the modalities of sharing the information and the model of revenue sharing is not clear. It can be the issue of contention among the different players in the collaborative research process.
3.
The most important problem is that who will proactively initiate the work and share the information at the first place. There is no clarity regarding the phase wise milestones of the project. Further, how the results will be delivered to the public free of cost is also not clear. So, these are the important problems.
Pl. repost other stop 2 and stop 3 questions for their proper answers!